OncoMatch/Clinical Trials/NCT05592626
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Is NCT05592626 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including STAR0602 and Irinotecan (Camptosar) for advanced solid tumors.
Treatment: STAR0602 · Irinotecan (Camptosar) · Docetaxel (Taxotere) — This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Biomarker criteria
Required: MLH1 loss
Required: MSH2 loss
Required: MSH6 loss
Required: MSI high
Required: PMS2 loss
Required: TMB high
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC Davis Comprehensive Cancer Center · Sacramento, California
- AdventHealth Celebration · Celebration, Florida
- University of Miami Sylvester Comprehensive Cancer Center · Miami, Florida
- The University of Kansas Cancer Center · Kansas City, Kansas
- National Institutes of Health · Bethesda, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05592626 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require MLH1?
Yes, MLH1 loss is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 loss is a required biomarker for enrollment.
Does this trial require MSH6?
Yes, MSH6 loss is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify